Cholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine (Fig. 1), enhance cholinergic transmission by inhibiting cholinesterase at the synaptic cleft.6,7 To date, there are no viable treatments for Alzheimer's disease.8 This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.